Systematic review / meta-analysis / 2012
Serenoa repens does not improve urinary symptoms or prostate size in BPH.
A systematic review evaluated 32 randomized controlled trials involving 5,666 men with benign prostatic hyperplasia receiving Serenoa repens for 4 to 72 weeks. In pooled analysis of two trials (n = 582), Serenoa repens did not reduce symptom scores compared to placebo (MD 0.25 points, 95% CI -0.58 to 1.07). Even at double and triple doses, treatment failed to meaningfully improve nocturia, peak urine flow, or prostate volume.
- Study type
- Systematic review and meta-analysis of randomized controlled trials
- Who was studied
- 5,666 men with symptomatic benign prostatic hyperplasia
- What was measured
- Urologic symptom scores, nocturia, urinary flow, and prostate size
THE PAPER
Serenoa repens for benign prostatic hyperplasia.
Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Cochrane Database Syst Rev, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.